GB1509707A - Immunological compounds - Google Patents

Immunological compounds

Info

Publication number
GB1509707A
GB1509707A GB41037/74A GB4103774A GB1509707A GB 1509707 A GB1509707 A GB 1509707A GB 41037/74 A GB41037/74 A GB 41037/74A GB 4103774 A GB4103774 A GB 4103774A GB 1509707 A GB1509707 A GB 1509707A
Authority
GB
United Kingdom
Prior art keywords
tumor
chloroethyl
cytotoxic
sept
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB41037/74A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle and Co Ltd
GD Searle LLC
Original Assignee
GD Searle and Co Ltd
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle and Co Ltd, GD Searle LLC filed Critical GD Searle and Co Ltd
Priority to GB41037/74A priority Critical patent/GB1509707A/en
Priority to FR7528837A priority patent/FR2285145A1/en
Priority to NL7511089A priority patent/NL7511089A/en
Priority to DE19752541931 priority patent/DE2541931A1/en
Priority to DK422475AA priority patent/DK141773B/en
Priority to SE7510505A priority patent/SE7510505L/en
Priority to JP50113541A priority patent/JPS5161640A/en
Publication of GB1509707A publication Critical patent/GB1509707A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Metal Rolling (AREA)
  • Peptides Or Proteins (AREA)

Abstract

1509707 Anti-tumor agents G D SEARLE & CO Ltd 16 Sept 1975 [20 Sept 1974] 41037/74 Heading A5B [Also in Division C3] An anti-tumor agent comprises, as cytotoxic agent, p-di (2-chloroethyl) amino-L-phenylalanine or N, N-bis (2-chloroethyl) p-phenylenediamine hydrochloride as cytotoxic agents bonded to a tumor specific antibody by peptide bonds. The anti-tumor agent preferably comprises 5 to 15 molecules of cytotoxic agent per molecule of tumor specific antibody. In the Examples, the cytotoxic agents are bonded to an immunoglobulin specific against EL4 lymphoma, and the activity of the complex is compared with (1) saline, (2) normal rat globulin/N, N-bis (2-chloroethyl) p-phenylene diamine complex, (3) EL4-immunoglobulin.
GB41037/74A 1974-09-20 1974-09-20 Immunological compounds Expired GB1509707A (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GB41037/74A GB1509707A (en) 1974-09-20 1974-09-20 Immunological compounds
FR7528837A FR2285145A1 (en) 1974-09-20 1975-09-19 IMMUNOLOGICAL COMPOUNDS AND PROCESS FOR THEIR PREPARATION
NL7511089A NL7511089A (en) 1974-09-20 1975-09-19 IMMUNOLOGICAL CONNECTIONS.
DE19752541931 DE2541931A1 (en) 1974-09-20 1975-09-19 IMMUNOLOGICAL COMPOUNDS
DK422475AA DK141773B (en) 1974-09-20 1975-09-19 Process for preparing an anti-tumor agent.
SE7510505A SE7510505L (en) 1974-09-20 1975-09-19 PROCEDURE FOR THE PREPARATION OF AN ANTITUMOR PRODUCT
JP50113541A JPS5161640A (en) 1974-09-20 1975-09-19 Koshuyozaino seizoho

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB41037/74A GB1509707A (en) 1974-09-20 1974-09-20 Immunological compounds

Publications (1)

Publication Number Publication Date
GB1509707A true GB1509707A (en) 1978-05-04

Family

ID=10417824

Family Applications (1)

Application Number Title Priority Date Filing Date
GB41037/74A Expired GB1509707A (en) 1974-09-20 1974-09-20 Immunological compounds

Country Status (7)

Country Link
JP (1) JPS5161640A (en)
DE (1) DE2541931A1 (en)
DK (1) DK141773B (en)
FR (1) FR2285145A1 (en)
GB (1) GB1509707A (en)
NL (1) NL7511089A (en)
SE (1) SE7510505L (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401592A (en) 1978-12-29 1983-08-30 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
GB2148299A (en) * 1983-09-01 1985-05-30 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
DE3513572A1 (en) * 1985-04-16 1986-10-16 Karl Prof. Dr.med. 7302 Ostfildern Theurer Preparation of products for specifically influencing the humoral and cellular immune response
US5773435A (en) * 1987-08-04 1998-06-30 Bristol-Myers Squibb Company Prodrugs for β-lactamase and uses thereof

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067971A (en) * 1976-05-13 1978-01-10 The Procter & Gamble Company Therapeutic composition
JPS54132503A (en) * 1978-04-07 1979-10-15 Kayaku Antibiotic Research Co Immune globulin combined neocarcinostatin
JPS5592325A (en) * 1978-12-29 1980-07-12 Kureha Chem Ind Co Ltd Antitumor agent and its preparation
JPS5665829A (en) * 1979-11-02 1981-06-03 Kureha Chem Ind Co Ltd Antitumor agent
JPS5665828A (en) * 1979-11-02 1981-06-03 Kureha Chem Ind Co Ltd Antitumor agent
DE3167679D1 (en) * 1980-03-31 1985-01-24 Inst Int Pathologie Cellulaire Pharmaceutical forms, their preparation and compositions containing the same
JPS58118520A (en) * 1982-01-09 1983-07-14 Hidematsu Hirai Antitumor proteinic complex and preparation thereof
JPS59186924A (en) * 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd Antitumor agent bonded with human immunoglobulin
JPS62228025A (en) * 1985-12-27 1987-10-06 Teijin Ltd Production of antibody complex
WO1988007553A1 (en) * 1987-03-26 1988-10-06 Teijin Limited Process for preparing antibody complex
AU649275B2 (en) * 1990-11-06 1994-05-19 Bristol-Myers Squibb Company Prodrugs for beta-lactamase and uses thereof
DE4122210C2 (en) * 1991-07-04 1999-04-01 Deutsches Krebsforsch Tumor-active compound-serum albumin conjugates, process for their preparation and their use

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401592A (en) 1978-12-29 1983-08-30 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
GB2148299A (en) * 1983-09-01 1985-05-30 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
DE3513572A1 (en) * 1985-04-16 1986-10-16 Karl Prof. Dr.med. 7302 Ostfildern Theurer Preparation of products for specifically influencing the humoral and cellular immune response
US5773435A (en) * 1987-08-04 1998-06-30 Bristol-Myers Squibb Company Prodrugs for β-lactamase and uses thereof

Also Published As

Publication number Publication date
FR2285145A1 (en) 1976-04-16
FR2285145B1 (en) 1980-05-30
DK141773B (en) 1980-06-16
JPS5161640A (en) 1976-05-28
SE7510505L (en) 1976-03-22
DK141773C (en) 1980-11-03
DE2541931A1 (en) 1976-04-01
NL7511089A (en) 1976-03-23
DK422475A (en) 1976-03-21

Similar Documents

Publication Publication Date Title
GB1509707A (en) Immunological compounds
CA2093928A1 (en) Monoclonal antibodies for detection and treatment of cancer
ATE155818T1 (en) NON-GLYCOSYLATED ANTI-CD3-IGG ANTIBODIES
HK1012841A1 (en) Pharmaceutical composition for the treatment or prevention of amalignant tumor
DK191985D0 (en) THERAPEUTIC ANTIBODY PREPARATIONS WITH EXTENDED SERUM Half-life
EP0420913A4 (en) Heterofunctional cellular immunological reagents, vaccines containing same and methods for the use of same
ATE123227T1 (en) CATIONIZED ANTIBODIES FOR TRANSMISSION THROUGH THE BLOOD-BRAIN BARRIER.
FI950062A0 (en) Photoactivation of proteins for conjugation purposes
GB1492997A (en) Insulin derivatives
DE3485289D1 (en) MONOCLONAL ANTIBODY VERSION FOR DIAGNOSTIC USE.
CA2149770A1 (en) Detection of hypoxia
GB1429195A (en) Psychopharmacologically active peptides
Nandedkar et al. Mn++ binding by plasma proteins
CA2036814A1 (en) Monoclonal antibodies against tumor-associated antigens, a process for the preparation thereof and the use thereof
ES8800604A1 (en) A tumor associated antigen.
CA2139518A1 (en) Antigenic regions of tlp complexes and antibodies against the same
KR850001531A (en) Hybridoma cell line producing monotrophic antibodies and monotrophic antibodies that recognize the common structure of the light chain of human internal leukocyte-2 (TCGF) and human immunoglobulin
GB1136039A (en) Improvements relating to immunosuppressive agents
GB1411553A (en) Motor vehicle exhaust system and mountings therefor
CA2038030A1 (en) Synthetic peptides which contain sequences from factor viia, and the use thereof
GB1463908A (en) 1-dimethylamino-methyl-6-substituted-4h-s-triazolo-4,3-a- 1,4-benzodiazepine
AU7145087A (en) Tumor-associated antigens (mol wt 160,000-170,000; 44,000-46,000; 29,000-35,000)
EP0089771A3 (en) Atcc hb8116 and its monoclonal anti-h-y antibody, hyclonalan
Wong et al. Binding of methylmercury by amino-acids: X-ray structure of DL-penicillaminatomethylmercury (II)
VTYURINA Moscow BIOLOGICHESKIYE MEMBRANY in Russian Vol 1, No 11, Nov &h (manuscript received 10 May 8k) pp II61-II70 VTYURINA, I. Yu., KURYATOV, AB, KISELEV, AV, KHOROSHILOVA, NI OVECHKINA, GV, ABDULAYEV, NG, TSETLIN, VI and VASILOV, RG,'Institute of Bioorganic Chemistry imeni MM Shemyakin, USSR Academy'of

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
PCNP Patent ceased through non-payment of renewal fee